Literature DB >> 24029121

Acute myeloid leukemia, version 2.2013.

Margaret R O'Donnell1, Martin S Tallman, Camille N Abboud, Jessica K Altman, Frederick R Appelbaum, Daniel A Arber, Eyal Attar, Uma Borate, Steven E Coutre, Lloyd E Damon, Jeffrey Lancet, Lori J Maness, Guido Marcucci, Michael G Martin, Michael M Millenson, Joseph O Moore, Farhad Ravandi, Paul J Shami, B Douglas Smith, Richard M Stone, Stephen A Strickland, Eunice S Wang, Kristina M Gregory, Maoko Naganuma.   

Abstract

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.

Entities:  

Mesh：

Year:  2013        PMID： 24029121      PMCID： PMC4161234          DOI： 10.6004/jnccn.2013.0127

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  18 in total

1.  Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

Authors:  Elihu Estey; Guillermo Garcia-Manero; Alessandra Ferrajoli; Stefan Faderl; Srdan Verstovsek; Dan Jones; Hagop Kantarjian
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

2.  A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study.

Authors:  Norio Asou; Yuji Kishimoto; Hitoshi Kiyoi; Masaya Okada; Yasukazu Kawai; Motohiro Tsuzuki; Kentaro Horikawa; Mitsuhiro Matsuda; Katsuji Shinagawa; Tohru Kobayashi; Shigeki Ohtake; Miki Nishimura; Masatomo Takahashi; Fumiharu Yagasaki; Akihiro Takeshita; Yukihiko Kimura; Masako Iwanaga; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

3.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

Authors:  P Fenaux; C Chastang; S Chevret; M Sanz; H Dombret; E Archimbaud; M Fey; C Rayon; F Huguet; J J Sotto; C Gardin; P C Makhoul; P Travade; E Solary; N Fegueux; D Bordessoule; J S Miguel; H Link; B Desablens; A Stamatoullas; E Deconinck; F Maloisel; S Castaigne; C Preudhomme; L Degos
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

4.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

Authors:  Z X Shen; G Q Chen; J H Ni; X S Li; S M Xiong; Q Y Qiu; J Zhu; W Tang; G L Sun; K Q Yang; Y Chen; L Zhou; Z W Fang; Y T Wang; J Ma; P Zhang; T D Zhang; S J Chen; Z Chen; Z Y Wang
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

5.  Curative strategies in acute promyelocytic leukemia.

Authors:  Martin S Tallman; Jessica K Altman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

6.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Authors:  Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.

Authors:  Lionel Adès; Agnes Guerci; Emmanuel Raffoux; Miguel Sanz; Patrice Chevallier; Simona Lapusan; Christian Recher; Xavier Thomas; Consuelo Rayon; Sylvie Castaigne; Olivier Tournilhac; Stephane de Botton; Norbert Ifrah; Jean-Yves Cahn; Eric Solary; Claude Gardin; Nathalie Fegeux; Dominique Bordessoule; Augustin Ferrant; Sandrine Meyer-Monard; Norbert Vey; Herve Dombret; Laurent Degos; Sylvie Chevret; Pierre Fenaux
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

8.  Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.

Authors:  Lionel Adès; Miguel A Sanz; Sylvie Chevret; Pau Montesinos; Patrice Chevallier; Emmanuel Raffoux; Edo Vellenga; Agnès Guerci; Arnaud Pigneux; Francoise Huguet; Consuelo Rayon; Anne Marie Stoppa; Javier de la Serna; Jean-Yves Cahn; Sandrine Meyer-Monard; Thomas Pabst; Xavier Thomas; Stéphane de Botton; Ricardo Parody; Juan Bergua; Thierry Lamy; Anne Vekhoff; Silvia Negri; Norbert Ifrah; Hervé Dombret; Augustin Ferrant; Dominique Bron; Laurent Degos; Pierre Fenaux
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

9.  All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Authors:  Martin S Tallman; Janet W Andersen; Charles A Schiffer; Frederick R Appelbaum; James H Feusner; William G Woods; Angela Ogden; Howard Weinstein; Lois Shepherd; Cheryl Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Christian Thiede; Sonia Maria Orlando; Simona Iacobelli; Felicetto Ferrara; Paola Fazi; Laura Cicconi; Eros Di Bona; Giorgina Specchia; Simona Sica; Mariadomenica Divona; Alessandro Levis; Walter Fiedler; Elisa Cerqui; Massimo Breccia; Giuseppe Fioritoni; Helmut R Salih; Mario Cazzola; Lorella Melillo; Angelo M Carella; Christian H Brandts; Enrica Morra; Marie von Lilienfeld-Toal; Bernd Hertenstein; Mohammed Wattad; Michael Lübbert; Matthias Hänel; Norbert Schmitz; Hartmut Link; Maria Grazia Kropp; Alessandro Rambaldi; Giorgio La Nasa; Mario Luppi; Fabio Ciceri; Olimpia Finizio; Adriano Venditti; Francesco Fabbiano; Konstanze Döhner; Michaela Sauer; Arnold Ganser; Sergio Amadori; Franco Mandelli; Hartmut Döhner; Gerhard Ehninger; Richard F Schlenk; Uwe Platzbecker
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245
View more
  51 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

2.  Acute myeloid leukemia therapy and the chosen people.

Authors:  E Estey; R P Gale
Journal:  Leukemia       Date:  2016-11-11       Impact factor: 11.528

3.  Drug Shortage Impacts Patient Receipt of Induction Treatment.

Authors:  Nancy G Hedlund; Zeynep Isgor; Jack Zwanziger; Damiano Rondelli; Stephanie Y Crawford; Denise M Hynes; Lisa M Powell
Journal:  Health Serv Res       Date:  2018-09-10       Impact factor: 3.402

4.  Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.

Authors:  Grace Kam; Richard Yiu; Yvonne Loh; Ai Leen Ang; Ling Ling Yueh; Yeow Tee Goh; Gee Chuan Wong
Journal:  Support Care Cancer       Date:  2014-08-27       Impact factor: 3.603

5.  Value of routine 'day 14' marrow exam in newly diagnosed AML.

Authors:  T Yezefski; H Xie; R Walter; J Pagel; P S Becker; P Hendrie; V Sandhu; K Shannon-Dorcy; J Abkowitz; F R Appelbaum; E Estey
Journal:  Leukemia       Date:  2014-09-10       Impact factor: 11.528

6.  Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment.

Authors:  Fang Xu; Chang-Xin Yin; Chun-Li Wang; Bing-Jie Ding; Qing-Xiu Zhong; Xue-Jie Jiang; Ling Jiang; Zhi-Xiang Wang; Fan-Yi Meng
Journal:  Biomed Rep       Date:  2018-07-02

7.  Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation.

Authors:  Catherine Jones; Temekka V LeDay; Alan M Miller
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-10

8.  Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.

Authors:  Ji-Hao Zhou; Hai-Qing Lin; Qi Shen; Li-Na Hu; Guo-Qiang Li; Xiong-Fei Sun; Xin-You Zhang
Journal:  Curr Med Sci       Date:  2018-03-15

9.  Alleviating the progression of acute myeloid leukemia (AML) by sulforaphane through controlling miR-155 levels.

Authors:  Mohsen Koolivand; Maryam Ansari; Fatemeh Piroozian; Soheila Moein; Kianoosh MalekZadeh
Journal:  Mol Biol Rep       Date:  2018-10-22       Impact factor: 2.316

Review 10.  Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Authors:  Christopher S Hourigan; Philip McCarthy; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-27       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.